Cardiac Guidance vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Caption Health
VS
by Pathway Labs

AI Verdict

Both Cardiac Guidance and EchoNext are FDA-cleared AI tools focused on cardiac health, making them adjacent competitors. Cardiac Guidance specializes in real-time AI-guided ultrasound image acquisition and interpretation for point-of-care diagnostics, ideal for users needing to perform and analyze echocardiograms. EchoNext, conversely, analyzes standard ECGs to detect hidden structural heart disease, offering a non-invasive screening tool for a broader range of healthcare settings.

Choose Cardiac Guidance if…

Choose Cardiac Guidance if your healthcare facility needs to empower a wider range of medical professionals, including those without extensive ultrasound experience, to perform and interpret diagnostic-quality cardiac ultrasounds at the point of care. This tool is ideal for improving accessibility to critical cardiac assessments and enabling earlier detection of heart conditions through real-time AI guidance and automated image acquisition. It's particularly well-suited for emergency medicine, cardiology, and radiology departments looking to streamline cardiac imaging workflows and enhance diagnostic capabilities with existing compatible ultrasound systems.

View Cardiac Guidance →

Choose EchoNext if…

Choose EchoNext if your primary goal is to leverage existing standard ECG data to non-invasively screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, across a broad patient population. This tool is best suited for practices and hospitals, from major institutions to community practices, that want to enhance their diagnostic capabilities by identifying at-risk patients early using readily available ECGs. It's particularly valuable for cardiology, family medicine, hospital medicine, and internal medicine specialties seeking an affordable, scalable solution for early disease detection and risk stratification through an integrated clinical decision support platform.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cardiac Guidance EchoNext
Pricing Contact vendor Starts at $600/month
Deployment Software accessory integrated with compatible general purpose diagnostic ultrasound systems (e.g., GE HealthCare Venue Family, Vscan Air SL, Terason uSmart 3200t Plus). Available through the OpenEvidence clinical decision support platform.
BAA Available Unknown Yes AI-estimated
FDA Status 1 AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiac Guidance

Cardiac Guidance provides real-time AI guidance with turn-by-turn instructions and a quality meter, enabling non-expert ultrasound users to acquire diagnostic-quality images with minimal training. This direct, interactive guidance for image acquisition makes it highly usable for a broader range of healthcare professionals. EchoNext, while analyzing standard ECGs, does not offer the same level of interactive guidance for data acquisition, focusing instead on interpretation of existing data.

Clinical Value

EchoNext

EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, with studies showing it outperforms cardiologists in accuracy. This offers significant value by identifying high-risk patients who might otherwise be missed, leading to earlier intervention. Cardiac Guidance focuses on improving the acquisition of cardiac ultrasound images, which is valuable for expanding access to quality diagnostics, but EchoNext's ability to detect hidden disease from a widely available, inexpensive test like an ECG presents a broader clinical impact for early screening.

Pricing & Value

EchoNext

EchoNext offers tiered pricing starting at $600/month, providing transparency and different options for various organizational sizes, along with potential annual discounts. Cardiac Guidance states 'contact vendor' for pricing, which lacks transparency. While both aim to reduce costs by improving diagnostics, EchoNext's clear pricing structure and its ability to leverage existing, inexpensive ECGs for early screening offer a more immediately quantifiable value proposition.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a strong existing infrastructure for deployment and integration within enterprise healthcare systems. It is also designed for broad access, from major hospitals to community practices. Cardiac Guidance is a software accessory integrated with compatible ultrasound systems, and while it's now part of GE HealthCare, its deployment is tied to specific hardware, which might present more integration challenges for diverse enterprise environments.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. Cardiac Guidance is innovative in its real-time AI guidance for cardiac ultrasound image acquisition, democratizing access to diagnostic-quality scans for non-experts. EchoNext is innovative in its ability to detect hidden structural heart disease from standard ECGs, outperforming cardiologists and potentially creating a new screening paradigm. Both address critical gaps in cardiac care through novel AI applications.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details about the ongoing support and documentation available for either Cardiac Guidance or EchoNext. Without this information, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cardiac Guidance EchoNext
Tool Name Cardiac Guidance EchoNext
Company Caption Health Pathway Labs
Description FDA-cleared AI tool that empowers healthcare professionals to acquire and interpret diagnostic-quality cardiac ultrasound images at the point of care, democratizing access to critical cardiac assessments. FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features Real-time AI guidance for cardiac ultrasound image acquisition, Turn-by-turn on-screen probe movement instructions, Automated quality assessment with a 'Quality Meter', Auto-capture of diagnostic-quality images and video clips, Automated left ventricular ejection fraction (EF) calculation (Caption Interpretation), Support for 10 standard echocardiographic views (e.g., PLAX, AP4, AP2), Compatibility with point-of-care ultrasound systems, Designed for use by non-expert ultrasound users AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support
Specialties Cardiology, Emergency Medicine, Radiology Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Cardiac Guidance and EchoNext.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cardiac Guidance is designed for real-time AI-guided cardiac ultrasound image acquisition at the point of care, making it suitable for specialties like Cardiology, Emergency Medicine, and Radiology, and enabling non-expert ultrasound users to acquire diagnostic-quality images. EchoNext, on the other hand, analyzes standard ECGs to detect hidden structural heart disease and is deployed through the OpenEvidence clinical decision support platform, fitting well within Cardiology, Family Medicine, Hospital Medicine, and Internal Medicine workflows by integrating into existing physician tools.
Cardiac Guidance assists in acquiring diagnostic-quality cardiac ultrasound images with automated quality assessment and auto-capture features, and has shown high interpretability and accuracy in detecting conditions like Stage B heart failure when used by novice users. EchoNext, an AI-powered ECG model, has demonstrated high diagnostic accuracy in detecting structural heart disease, outperforming cardiologists in studies with an AUROC of 85.2% and an accuracy of 77% compared to cardiologists' 64% without AI assistance.
Cardiac Guidance is designed for use by non-expert ultrasound users and requires only basic imaging knowledge and short video training courses to enable clinicians to capture diagnostic-quality cardiac images. EchoNext, integrated into the OpenEvidence clinical decision support platform, is designed to fit into existing physician workflows, suggesting a potentially lower learning curve for integration into daily practice as it leverages a platform many physicians already use.
Cardiac Guidance provides real-time AI guidance for probe movement, automated quality assessment, and auto-capture of diagnostic-quality images and video clips, including automated left ventricular ejection fraction (EF) calculation, directly supporting immediate cardiac assessments. EchoNext analyzes standard 12-lead ECGs to identify risk for various structural heart diseases like heart failure, valve disease, and pulmonary hypertension, acting as a screening tool to indicate when a follow-up echocardiogram is warranted.
Cardiac Guidance is deployed as a software accessory integrated with compatible general-purpose diagnostic ultrasound systems, suggesting scalability through its compatibility with existing hardware and its design for use by non-expert users across various point-of-care settings. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. clinicians, facilitating broad access and deployment across major hospitals to community practices without requiring a separate workflow or system.
The provided information does not explicitly detail specific audit-trail features for either Cardiac Guidance or EchoNext. However, in general, EHR systems, with which tools like EchoNext integrate, often include robust audit capabilities for data access and modifications to support compliance and accountability.
The provided information does not detail security postures beyond HIPAA compliance for either Cardiac Guidance or EchoNext. However, given that EchoNext integrates with clinical decision support platforms and EHRs, these platforms typically employ advanced security measures for data exchange and patient information.
AI Tool Finder
AI-powered search. Results may not be comprehensive.